Stryker Corporation

NYSE:SYK Rapport sur les actions

Capitalisation boursière : US$130.9b

Stryker Croissance future

Future contrôle des critères 2/6

Stryker devrait augmenter ses bénéfices et son chiffre d'affaires de 15.3% et de 8% par an respectivement. Le BPA devrait croître de de 15.1% par an. Le rendement des capitaux propres devrait être 22% dans 3 ans.

Informations clés

15.3%

Taux de croissance des bénéfices

15.07%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices16.8%
Taux de croissance des recettes8.0%
Rendement futur des capitaux propres21.96%
Couverture par les analystes

Good

Dernière mise à jour03 Aug 2026

Mises à jour récentes de la croissance future

Article d’analyse • May 04

Stryker Corporation Just Missed Earnings - But Analysts Have Updated Their Models

As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...

Recent updates

Seeking Alpha • Jul 08

Stryker: Medtech On Sale, Benefiting From Industry Growth

Summary Stryker Corporation offers a compelling medtech investment, benefiting from robust industry growth and an innovation-led strategy. SYK trades at a 13% discount to fair value, with a forward P/E of 20.1 versus a 10-year average of 25.6. Consensus expects SYK’s adjusted diluted EPS to compound at 11.2% annually through 2028, supporting high single-digit dividend growth. Key risks include cybersecurity vulnerabilities and fierce competition, but SYK’s diversified portfolio and disciplined capital allocation underpin its long-term outlook. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 14

SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Recovery Prospects

Stryker's fair value estimate has been adjusted slightly lower to $386.80 from $389.24 as analysts temper price targets in response to lower utilization expectations, inflation headwinds, and more conservative long term margin and P/E assumptions. Analyst Commentary Recent Street research on Stryker has been active, with most updates focused on resetting price targets and reassessing long term assumptions around utilization, inflation, and margins.
Mise à jour du récit • May 31

SYK: Hospital Digitization And Cyber Resilience Will Drive 2026 Rebound Potential

Analysts have trimmed Stryker's updated price target slightly, reflecting a minor change of about $0.11 and combining a series of recent target cuts from multiple firms with one modest increase, as they reassess assumptions around discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts who recently raised or affirmed higher targets highlight what they see as healthy fundamentals in U.S. medical technology, which they argue can support Stryker's growth assumptions that underpin current P/E expectations.
Mise à jour du récit • May 14

SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Upside

Analysts have nudged Stryker's fair value estimate lower to about $389 from roughly $419, as a wave of reduced price targets led by firms like Truist, Barclays and others has been paired with updated assumptions for slightly lower future P/E multiples, alongside higher projected revenue growth and profit margins. Analyst Commentary Recent research around Stryker has tilted more cautious, with a cluster of reduced price targets across multiple firms, offset by a smaller group of more supportive views.
Article d’analyse • May 04

Stryker Corporation Just Missed Earnings - But Analysts Have Updated Their Models

As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...
Mise à jour du récit • Apr 21

SYK: Diversified Portfolio And Hospital Digitization Will Support 2026 Upside

Analysts have trimmed Stryker's fair value estimate by about $6 to $419, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, and a slightly lower future P/E multiple, even as profit margin expectations are marginally higher. Analyst Commentary Recent Street research on Stryker shows a mix of optimism about the company’s long term growth drivers and caution around near term valuation and risk.
Mise à jour du récit • Apr 06

SYK: Diversified Growth Drivers And Robotics Adoption Will Support 2026 Upside

The updated analyst price target for Stryker edges slightly higher to about $425 per share, as analysts balance recent target trims with continued support from firms highlighting a healthy U.S. medtech backdrop, diversified growth drivers, and potential near term catalysts. Analyst Commentary Recent research paints a mixed but generally constructive picture for Stryker, with several firms adjusting price targets and ratings as they reassess growth drivers, execution, and valuation against a still supportive U.S. medtech backdrop.
Mise à jour du récit • Mar 22

SYK: Diversified Portfolio And Robotics Adoption Will Support 2026 Upside

Analysts have trimmed the Stryker fair value estimate by less than $1 to about $424 per share, reflecting a slightly higher discount rate and a modestly lower assumed future P/E multiple. Recent research cites mixed price target moves and differing views on near term catalysts and sector trends.
Mise à jour du récit • Mar 07

SYK: Diversified Product Reach And Robotics Expansion Will Support 2026 Upside

The analyst fair value estimate for Stryker has edged up by about $0.50 to $424.90, as analysts factor in recent price target moves, including several Outperform ratings that highlight the company's broader product reach and diversified growth profile. Analyst Commentary Recent research on Stryker reflects a mix of optimism about the company’s growth profile and some caution on valuation and sector level risks.
Mise à jour du récit • Feb 20

SYK: Diversified Medtech Portfolio And Robotics Execution Will Support 2026 Upside

Analysts made a modest trim to their blended Stryker price target, reflecting mixed recent revisions that range from higher targets up to $465 with Outperform ratings to lower targets near $390 and $399 with a Hold rating, as they weigh the company's broader product reach and expected sales and earnings trends against valuation and sector-level risks. Analyst Commentary Recent research on Stryker reflects a split view, with some analysts leaning into the growth story and others more guarded on valuation and sector risks.
Article d’analyse • Feb 09

Stryker's (NYSE:SYK) Earnings Seem To Be Promising

Stryker Corporation's ( NYSE:SYK ) recent earnings report didn't offer any surprises, with the shares unchanged over...
Article d’analyse • Feb 07

Stryker (NYSE:SYK) Is Due To Pay A Dividend Of $0.88

Stryker Corporation ( NYSE:SYK ) will pay a dividend of $0.88 on the 30th of April. This takes the annual payment to...
Mise à jour du récit • Feb 06

SYK: Orthopedics And Robotics Execution Will Support 2026 Rebound In Medtech Sentiment

Analysts have reduced their fair value estimate for Stryker by about $3 to $424, reflecting slightly softer revenue growth assumptions, a future P/E multiple closer to 34, and a modestly higher profit margin outlook following recent mixed price target changes across Wall Street. Analyst Commentary Recent research coverage on Stryker reflects a mix of optimism and caution, with several firms adjusting price targets and ratings in different directions.
Mise à jour du récit • Jan 22

SYK: Orthopedics And Robotics Execution Will Support 2026 Upside Potential

Analysts have inched their average price target on Stryker higher, with a modest fair value lift to about US$427.40, as they weigh mixed target changes across firms against ongoing views that the company remains a high quality large-cap MedTech name heading into 2026. Analyst Commentary Recent Street research on Stryker shows a split tape, with several firms lifting targets and ratings while others trim fair values or stay neutral.
Mise à jour du récit • Jan 08

SYK: Orthopedics Strength And Robotics Adoption Will Support Long-Term Upside

Narrative Update: Stryker The analyst price target for Stryker has been adjusted slightly lower to reflect a fair value estimate of about $427.22. Analysts point to mixed but generally solid recent research that highlights compressed forward multiples, updated targets in the $390 to $453 range, and ongoing views of Stryker as a high quality large cap MedTech name, with attractive entry points and healthy procedure and CapEx trends into 2026.
Mise à jour du récit • Dec 19

SYK: Expanding Orthopedics And Robotics Footprint Will Drive Long-Term Upside Potential

Analysts have modestly trimmed our fair value estimate for Stryker to approximately $428 from about $433 per share, reflecting a slightly higher discount rate and lower valuation multiple, even as they acknowledge improving revenue growth, rising profit margins, and continued operating leverage highlighted in recent research updates and investor day commentary. Analyst Commentary Street research on Stryker has been active in recent weeks, with modestly higher and lower price targets reflecting a balanced mix of optimism on execution and caution on MedTech sentiment and relative growth.
Article d’analyse • Dec 14

Stryker (NYSE:SYK) Has Announced That It Will Be Increasing Its Dividend To $0.88

Stryker Corporation's ( NYSE:SYK ) periodic dividend will be increasing on the 30th of January to $0.88, with investors...
Article d’analyse • Sep 08

Does Stryker (NYSE:SYK) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse • Aug 08

Investors Can Find Comfort In Stryker's (NYSE:SYK) Earnings Quality

NYSE:SYK 1 Year Share Price vs Fair Value Explore Stryker's Fair Values from the Community and select yours The most...

Prévisions de croissance des bénéfices et des revenus

NYSE:SYK - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202832,0006,5285,8227,92022
12/31/202729,5995,5605,0316,62127
12/31/202627,2944,8823,8605,17127
6/30/202625,8373,7294,7025,525N/A
3/31/202625,2703,3374,5715,375N/A
12/31/202525,1163,2464,2835,044N/A
9/30/202524,3812,9434,0734,832N/A
6/30/202523,8182,9184,0244,766N/A
3/31/202523,2182,8593,5774,288N/A
12/31/202422,5952,9933,4874,242N/A
9/30/202421,9743,5903,2053,839N/A
6/30/202421,3893,4482,8033,415N/A
3/31/202420,9633,3612,8583,470N/A
12/31/202320,4983,1653,1363,711N/A
9/30/202319,8852,5852,5683,186N/A
6/30/202319,4552,7092,4173,025N/A
3/31/202318,9522,6272,2672,866N/A
12/31/202218,4492,3582,0362,624N/A
9/30/202217,9482,4572,0152,621N/A
6/30/202217,6292,0792,0672,665N/A
3/31/202217,4302,0152,4533,014N/A
12/31/202117,1081,9942,7383,263N/A
9/30/202116,6691,9003,0163,500N/A
6/30/202116,2462,0832,9733,396N/A
3/31/202114,7161,4082,7123,138N/A
12/31/202014,3511,5992,7903,277N/A
9/30/202014,2201,7562,2542,775N/A
6/30/202014,0701,6011,9602,575N/A
3/31/202014,9562,164N/A2,469N/A
12/31/201914,8842,083N/A2,191N/A
9/30/201914,5493,426N/A2,502N/A
6/30/201914,2043,550N/A2,491N/A
3/31/201913,8763,522N/A2,626N/A
12/31/201813,6013,553N/A2,610N/A
9/30/201813,2761,236N/A2,243N/A
6/30/201813,0401,080N/A1,704N/A
3/31/201812,7301,019N/A1,705N/A
12/31/201712,4441,020N/A1,559N/A
9/30/201712,1301,779N/A1,538N/A
6/30/201711,9571,700N/A1,961N/A
3/31/201711,7851,689N/A1,804N/A
12/31/201611,3251,647N/A1,915N/A
9/30/201610,8831,659N/A1,928N/A
6/30/201610,4701,605N/A917N/A
3/31/201610,0621,617N/A781N/A
12/31/20159,9461,439N/A981N/A
9/30/20159,8491,177N/A907N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de SYK ( 15.3% par an) est supérieure au taux d'épargne ( 3.5% ).

Bénéfices vs marché: Les bénéfices de SYK ( 15.3% par an) devraient croître plus lentement que le marché US ( 16.5% par an).

Croissance élevée des bénéfices: Les bénéfices de SYK devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de SYK ( 8% par an) devrait croître plus lentement que le marché de US ( 12.7% par an).

Croissance élevée des revenus: Le chiffre d'affaires de SYK ( 8% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de SYK devrait être élevé dans 3 ans ( 22 %)

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/08/04 01:12
Cours de l'action en fin de journée2026/08/03 00:00
Les revenus2026/06/30
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Stryker Corporation est couverte par 54 analystes. 27 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
David ToungArgus Research Company
Jeffrey JohnsonBaird
Adam FeinsteinBarclays